Results 21 to 30 of about 6,247,192 (199)
Results of the Childhood Cancer and Leukaemia Group's United Kingdom Relapsed Wilms Tumour Trial
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background The United Kingdom relapsed Wilms tumour (UKW‐R) trial aimed to improve the historically low survival rates after relapse of Wilms tumour (WT) through a prospective national risk‐stratified protocol. The trial also evaluated efficacy and toxicity of high‐dose melphalan.
Sucheta J. Vaidya +10 more
wiley +1 more source
$$d_{N \Omega }$$ d N Ω production in $$\Omega d$$ Ω d scattering process
European Physical Journal C: Particles and FieldsIn the present work, we propose to investigate the production of $$d_{N \Omega }$$ d N Ω in the $$\Omega ^{-} d \rightarrow p d_{N \Omega }^-$$ Ω - d → p d N Ω - process by utilizing an effective Lagrangian approach, where $$d_{N \Omega }$$ d N Ω is ...
Quan-Yun Guo, Jing Liu, Dian-Yong Chen
doaj +1 more source
N $$ \mathcal{N} $$ -extended D = 4 supergravity, unconventional SUSY and graphene
Journal of High Energy Physics, 2020 We derive a 2+1 dimensional model with unconventional supersymmetry at the boundary of an AdS4 N $$ \mathcal{N} $$ -extended supergravity, generalizing previous results. The (unconventional) extended supersymmetry of the boundary model is instrumental in
L. Andrianopoli +6 more
doaj +1 more source
Glossa, 2020 The DP Hypothesis has recently come under intense criticism (Bruening 2009, Bruening et al. 2018). In the face of this criticism, several responses have been offered. This paper addresses three such responses and shows that they are without force. First,
Benjamin Bruening
doaj +2 more sources
Pediatric Blood &Cancer, EarlyView.ABSTRACT Purpose Chemoimmunotherapy with irinotecan, temozolomide, and dinutuximab (I/T/DIN) has emerged as first‐line therapy for relapsed/refractory (r/r) high‐risk neuroblastoma (HRNB) in North America. Topotecan and cyclophosphamide (T/C) are often used in combination with dinutuximab in the setting of lack of response, progression, or incomplete ...
Benjamin J. Lerman +17 more
wiley +1 more source
Clinical Course and Impact of Breaks in Therapy for Children With Relapsed/Refractory Solid Tumors
Pediatric Blood &Cancer, EarlyView.ABSTRACT Introduction Pediatric relapsed or refractory (R/R) solid tumors carry a dismal prognosis, and postrelapse patient experiences are not well described. We present postrelapse outcomes, including number of R/R events and subsequent therapy regimens.
Matthew T. McEvoy +5 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Neuropsychological complications may impair the qualitative prognosis of patients with pediatric brain tumors. However, multifaceted evaluations cannot be conducted in all patients because they are time consuming and burdensome for patients.
Ami Tabata +9 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Patients with high‐risk neuroblastoma who either are refractory to induction chemotherapy or relapse following multi‐modal treatment have a dismal prognosis. Based on data from the BEACON trial, since 2021 the UK national guidelines recommend bevacizumab, irinotecan, and temozolomide (BIT) for patients with relapsed/refractory ...
Thomas J. Jackson +20 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Background Alveolar soft part sarcoma (ASPS) is a rare soft tissue sarcoma occurring most commonly in adolescence and young adulthood. Methods We present the clinical characteristics, treatments, and outcomes of patients with newly diagnosed ASPS enrolled on the Children's Oncology Group study ARST0332.
Jacquelyn N. Crane +11 more
wiley +1 more source